Ribbon Acquisition Corp. (RIBB) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Ribbon Acquisition Corp. is a Cayman Islands exempted company and a Special Purpose Acquisition Company (SPAC) incorporated on July 17, 2024. The company completed its Initial Public Offering (IPO) on January 16, 2025, raising $50 million. As of September 30, 2025, the company has not commenced operations other than organizational activities and the search for a business combination. The reporting period covers the quarter and nine months ended September 30, 2025.
Key Financial Metrics
| Metric | Value (as of/for period ended Sept 30, 2025) |
|---|---|
| Total Assets | $51,580,219 |
| Cash and Cash Equivalents (Outside Trust) | $59,909 |
| Trust Account Balance | $51,461,310 |
| Total Liabilities | $2,309,001 |
| Deferred Underwriting Commission | $2,000,000 |
| Net Income (3 Months) | $62,142 |
| Net Income (9 Months) | $569,295 |
| Operating Expenses (9 Months) | $892,007 |
| Trust Income (9 Months) | $1,461,302 |
| Working Capital Deficit | ($190,092) |
Material Changes vs. Prior Period
- Asset Growth: Total assets increased from $508,662 at December 31, 2024, to $51,580,219 at September 30, 2025, driven by the IPO proceeds held in the Trust Account.
- Profitability: The company reported a net loss of $10,305 for the period from inception (July 17, 2024) through September 30, 2024. In contrast, the nine months ended September 30, 2025, resulted in a net income of $569,295, primarily due to interest income earned on the Trust Account ($1.46 million) exceeding operating expenses ($892,007).
- Equity Structure: Following the IPO, 5,000,000 Class A ordinary shares are subject to possible redemption, valued at $48,204,536. The Sponsor surrendered 187,500 Class B shares in January 2025, leaving 1,250,000 Class B shares outstanding.
Outlook, Management Commentary, and Risks
- Business Combination: On June 30, 2025, the company entered into a Business Combination Agreement with DRC Medicine Inc., a Japanese company focused on AI-powered allergy and infection diagnostic kits. The transaction involves a share exchange and the domestication of Ribbon from the Cayman Islands to Delaware.
- Going Concern: Management has determined that the mandatory liquidation requirement if a business combination is not completed by January 16, 2026, raises substantial doubt about the company's ability to continue as a going concern. The financial statements do not include adjustments that might result from this uncertainty.
- Liquidity: The company has a working capital deficit of $190,092. It relies on the Trust Account for the business combination and limited cash outside the trust for working capital. The Sponsor has provided a $1,000 working capital loan and may provide additional loans up to $300,000.
- Risks: Key risks include the failure to consummate the business combination within the 12-month window (subject to extension), the potential for the Trust Account value to decline (though invested in U.S. Treasuries), and the Sponsor's ability to satisfy indemnification obligations if third-party claims reduce Trust funds below $10.00 per share.
Investor Verification Checklist
- Transaction Status: Verify the current status of the Business Combination Agreement with DRC Medicine and any conditions precedent to closing.
- Redemption Rights: Confirm the redemption price per share and the timeline for shareholder votes regarding the proposed merger.
- Going Concern: Review the company's plan to extend the combination period if the deal is not closed by January 16, 2026, to avoid automatic liquidation.
- Deferred Fees: Note the $2,000,000 deferred underwriting commission payable only upon successful completion of the business combination.
- Trust Account: Monitor the balance of the Trust Account ($51.46 million) to ensure it remains sufficient to cover the $10.00 per share redemption value for public shareholders.